Long-Term Outcomes After Melody Transcatheter Pulmonary Valve Replacement in the US Investigational Device Exemption Trial.
Thomas K JonesDoff B McElhinneyJulie A VincentWilliam E HellenbrandJohn P CheathamDarren P BermanEvan M ZahnDanyal M KhanJohn F RhodesShicheng WengLisa J BergersenPublished in: Circulation. Cardiovascular interventions (2021)
Ten-year outcomes from the Melody Investigational Device Exemption trial affirm the benefits of Melody TPV replacement in the lifetime management of patients with RVOT conduits and bioprosthetic pulmonary valves by providing sustained symptomatic and hemodynamic improvement in the majority of patients. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00740870.
Keyphrases
- aortic valve
- phase ii
- end stage renal disease
- mitral valve
- clinical trial
- pulmonary hypertension
- study protocol
- phase iii
- ejection fraction
- newly diagnosed
- chronic kidney disease
- aortic stenosis
- transcatheter aortic valve replacement
- prognostic factors
- open label
- randomized controlled trial
- coronary artery disease
- patient reported